Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Ionis Pharmaceuticals Inc (IONS)  
$40.93 1.35 (3.19%) as of 4:30 Tue 5/7


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 143,470,000
Market Cap: 5.87(B)
Last Volume: 998,037 Avg Vol: 995,265
52 Week Range: $35.18 - $53.55
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  292
Guru Rank Value     : 4.1
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Ionis Pharmaceuticals is engaged in RNA-targeted therapeuty. Co.'s commercial products are SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA injection for intrathecal use is a survival motor neuron-2 directed antisense medicine indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. TEGSEDI injection is an RNA-targeted medicine indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 5,298 463,764 501,366 628,895
Total Sell Value $221,558 $23,296,725 $24,905,844 $29,967,993
Total People Sold 3 12 13 13
Total Sell Transactions 3 43 51 77
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 1118
  Page 6 of 45  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2023-02-06 4 S $40.67 $57,464 D/D (1,413) 24,946 -3%     
   Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc   •       –      –    2023-02-06 4 S $40.66 $58,997 D/D (1,451) 21,227 -3%     
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2023-02-06 4 S $40.86 $78,460 D/D (1,920) 41,581 -3%     
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2023-02-06 4 S $40.57 $73,560 D/D (1,813) 69,651 -3%     
   Monia Brett P Chief Executive Officer   •       •      –    2023-02-06 4 S $40.69 $1,003,153 D/D (24,651) 145,305 -3%     
   Geary Richard S EVP, Chief Development Officer   •       –      –    2023-02-06 4 S $40.66 $78,070 D/D (1,920) 72,385 -3%     
   Swayze Eric EVP Research   •       –      –    2023-02-06 4 S $40.79 $74,031 D/D (1,815) 31,941 -3%     
   Hougen Elizabeth L EVP, Finance & CFO   •       –      –    2023-02-06 4 S $40.59 $84,392 D/D (2,079) 75,496 -3%     
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2023-02-03 4 A $0.00 $0 D/D 4,033 26,359     -
   Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc   •       –      –    2023-02-03 4 A $0.00 $0 D/D 4,140 22,678     -
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2023-02-03 4 A $0.00 $0 D/D 3,822 43,501     -
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2023-02-03 4 A $0.00 $0 D/D 3,609 71,464     -
   Monia Brett P Chief Executive Officer   •       •      –    2023-02-03 4 A $0.00 $0 D/D 49,093 169,956     -
   Geary Richard S EVP, Chief Development Officer   •       –      –    2023-02-03 4 A $0.00 $0 D/D 3,822 74,305     -
   Swayze Eric EVP Research   •       –      –    2023-02-03 4 A $0.00 $0 D/D 3,715 33,756     -
   Hougen Elizabeth L EVP, Finance & CFO   •       –      –    2023-02-03 4 A $0.00 $0 D/D 4,140 77,575     -
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2023-01-31 4 AS $39.71 $178,700 D/D (4,500) 39,679 2%     
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2023-01-30 4 AS $39.42 $177,372 D/D (4,500) 44,179 6%     
   Baroldi Joseph EVP, Chief Business Officer   •       –      –    2023-01-18 4 S $39.79 $14,920 I/I (375) 851 -2%     
   Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc   •       –      –    2023-01-18 4 S $39.55 $148,223 D/D (3,748) 18,538 -2%     
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2023-01-18 4 S $39.57 $188,052 D/D (4,752) 22,326 -2%     
   Geary Richard S EVP, Chief Development Officer   •       –      –    2023-01-18 4 S $39.57 $311,525 D/D (7,873) 70,483 -2%     
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2023-01-18 4 S $38.89 $271,356 D/D (6,978) 67,855 -2%     
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2023-01-18 4 S $39.49 $309,480 D/D (7,836) 48,679 -2%     
   Hougen Elizabeth L EVP, Finance & CFO   •       –      –    2023-01-18 4 S $39.70 $328,721 D/D (8,280) 73,435 -2%     

  1118 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 6 of 45
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed